PGNX Share Price

Open 8.09 Change Price %
High 8.13 1 Day -0.38 -4.67
Low 7.67 1 Week -0.70 -8.28
Close 7.75 1 Month -3.50 -31.11
Volume 921850 1 Year 2.22 40.14
52 Week High 11.72
52 Week Low 4.00
PGNX Important Levels
Resistance 2 8.18
Resistance 1 8.00
Pivot 7.85
Support 1 7.50
Support 2 7.32
NASDAQ USA Most Active Stocks
ASTI 0.00 0.00%
FNFG 10.18 -0.20%
SIRI 5.07 0.00%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
ESSX 0.22 69.23%
MYRX 0.08 60.00%
CGEI 0.35 59.09%
LOCM 0.09 50.00%
RITT 0.03 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CARV 4.90 22.81%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Progenics Pharmaceuticals Inc. (NASDAQ: PGNX)

PGNX Technical Analysis 2
As on 21st Apr 2017 PGNX Share Price closed @ 7.75 and we RECOMMEND Buy for LONG-TERM with Stoploss of 7.43 & Strong Sell for SHORT-TERM with Stoploss of 10.02 we also expect STOCK to react on Following IMPORTANT LEVELS.
PGNX Target for April
1st Target up-side 10.91
2nd Target up-side 11.94
3rd Target up-side 12.97
1st Target down-side 7.97
2nd Target down-side 6.94
3rd Target down-side 5.91
PGNX Other Details
Segment EQ
Market Capital 99951264.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.progenics.com
PGNX Address
PGNX
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-789-2800
Fax: 914-789-2817
PGNX Latest News
Interactive Technical Analysis Chart Progenics Pharmaceuticals Inc. ( PGNX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Progenics Pharmaceuticals Inc.
PGNX Business Profile
Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers. In gastroenterology, its first commercial product is RELISTOR subcutaneous injection. Its principal product candidate is PSMA ADC, a fully human monoclonal antibody-drug conjugate directed against prostate specific membrane antigen, a protein found at high levels on the surface of prostate cancer cells and also on the neovasculature of a number of other types of solid tumors. In January 2013, the Company acquired Molecular Insight Pharmaceuticals, Inc.